Lymphovascular and neural regulation of metastasis: Shared tumour signalling pathways and novel therapeutic approaches

Best Practice and Research: Clinical Anaesthesiology

Volumn 27, Issue 4, 2013, Pages 409-425

  Le, Caroline P ^a   Karnezis, Tara ^b,c   Achen, Marc G ^b,c   Stacker, Steven A ^b,c   Sloan, Erica K ^a,b,d  

^a MONASH UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiogenesis; beta blocker; lymphangiogenesis; nerve fibres; NSAID; SNS; sympathetic nervous system; vasculature

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; AFLIBERCEPT; ANGIOPOIETIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; ETODOLAC; IBUPROFEN; INTEGRIN; KETOPROFEN; MATRIX METALLOPROTEINASE; NAPROXEN; PAZOPANIB; PLACENTAL GROWTH FACTOR; PROPRANOLOL; ROFECOXIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ADRENERGIC SYSTEM; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD VESSEL FUNCTION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHRONIC STRESS; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTRACELLULAR SIGNALING; LYMPH VESSEL; LYMPHANGIOGENESIS; MEDIATOR; METASTASIS; METASTATIC COLORECTAL CANCER; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STOMACH CANCER; STRESS; SYMPATHETIC NERVE; TUMOR MICROENVIRONMENT;

ANGIOGENESIS; BETA-BLOCKER; LYMPHANGIOGENESIS; NERVE FIBRES; NSAID; SNS; SYMPATHETIC NERVOUS SYSTEM; VASCULATURE;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; LYMPHANGIOGENESIS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84888429760     PISSN: 15216896     EISSN: 1532169X     Source Type: Journal    
DOI: 10.1016/j.bpa.2013.10.008     Document Type: Review

References (185)

1. N.A. Bhowmick, E.G. Neilson, and H.L. Moses Stromal fibroblasts in cancer initiation and progression Nature (London) 432 7015 2004 332 337
2. M.L. Macheda, and S.A. Stacker Importance of Wnt signaling in the tumor stroma microenvironment Curr Cancer Drug Targets 8 6 2008 454 465
3. D. Hanahan, and L.M. Coussens Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 21 3 2012 309 322
4. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
5. P. Carmeliet Blood vessels and nerves: common signals, pathways and diseases Nat Rev Genet 4 9 2003 710 720
6. K. Alitalo The lymphatic vasculature in disease Nature Med 17 11 2011 1371 1380
7. M.G. Achen, B.K. McColl, and S.A. Stacker Focus on lymphangiogenesis in tumor metastasis Cancer Cell 7 2 2005 121 127
8. R.H. Adams, and K. Alitalo Molecular regulation of angiogenesis and lymphangiogenesis Nature Rev Mol Cell Biol 8 6 2007 464 478
9. I.J. Fidler The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited Nature Rev Cancer 3 6 2003 453 458
10. I.J. Fidler The biology of cancer metastasis Semin Cancer Biol 21 2 2011 71
11. R.H. Farnsworth, M. Lackmann, and M.G. Achen Vascular remodeling in cancer Oncogene 2013, Aug 5 10.1038/onc.2013.304 [Epub ahead of print]
12. S.A. Stacker Lymphangiogenesis and cancer metastasis Nat Rev Cancer 2 2002 573 583
13. T. Karnezis VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium Cancer Cell 21 2 2012 181 195
14. W.M. Cannon Official medical experts Cal State J Med 13 1 1915 13 15
15. E.K. Sloan Social stress enhances sympathetic innervation of primate lymph nodes: mechanisms and implications for viral pathogenesis J Neurosci 27 33 2007 8857 8865
16. D.G. Powe Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study Breast Cancer Res Treat 130 2011 457 463
17. M. Shi The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells Breast Cancer Res Treat 125 2 2011 351 362
18. S. Moretti Beta-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines Lab Invest 93 3 2013 279 290
19. E.V. Yang Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression Brain Behav Immun 23 2 2009 267 275
20. E.K. Sloan The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res 70 18 2010 7042 7052
21. J.P. Campbell Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice PLoS Biol 10 7 2012 e1001363
22. S. Ben-Eliyahu Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system Brain Behav Immun 5 2 1991 193 205
23. S. Ben-Eliyahu Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors Neuroimmunomodulation 8 3 2000 154 164
24. P.H. Thaker Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat Med 12 8 2006 939 944
25. C. Magnon Autonomic nerve development contributes to prostate cancer progression Science 341 6142 2013 1236361
26. S. Hassan Behavioral stress accelerates prostate cancer development in mice J Clin Invest 123 2 2013 874 886
27. D. Palm The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers Int J Cancer 118 11 2006 2744 2749
28. D.M. Lamkin Chronic stress enhances progression of acute lymphoblastic leukemia via beta-adrenergic signaling Brain Behav Immun 26 4 2012 635 641
29. S. Inbar Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity PLoS One 6 4 2011 e19246
30. C. Perez Pinero Involvement of alpha2- and beta2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation Br J Pharmacol 166 2 2012 721 736
31. M. Benish Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis Ann Surg Oncol 15 7 2008 2042 2052
32. Y. Chida, M. Hamer, and J. Wardle Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 5 8 2008 466 475
33. C.H. Kroenke Social networks, social support, and survival after breast cancer diagnosis J Clin Oncol 24 7 2006 1105 1111
34. P. Reynolds Use of coping strategies and breast cancer survival: results from the Black/White Cancer Survival Study Am J Epidemiol 152 10 2000 940 949
35. K. Ell Social relations, social support and survival among patients with cancer J Psychosom Res 36 6 1992 531 541
36. H. Soler-Vila, S.V. Kasl, and B.A. Jones Prognostic significance of psychosocial factors in African-American and white breast cancer patients: a population-based study Cancer 98 6 2003 1299 1308
37. J. Barraclough Life events and breast cancer prognosis BMJ 304 6834 1992 1078 1081
38. J. Graham Stressful life experiences and risk of relapse of breast cancer: observational cohort study BMJ 324 7351 2002 1420
39. B.L. Andersen Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants Clin Cancer Res 16 12 2010 3270 3278
40. B.L. Andersen Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial Cancer 113 12 2008 3450 3458
41. K. Lillberg Stressful life events and risk of breast cancer in 10,808 women: a cohort study Am J Epidemiol 157 5 2003 415 423
42. M. Ewertz Bereavement and breast cancer Br J Cancer 53 5 1986 701 703
43. I. Levav Cancer incidence and survival following bereavement Am J Public Health 90 10 2000 1601 1607
44. C. Johansen, and J.H. Olsen Psychological stress, cancer incidence and mortality from non-malignant diseases Br J Cancer 75 1 1997 144 148
45. A. Kvikstad Widowhood and divorce related to cancer risk in middle-aged women. A nested case-control study among Norwegian women born between 1935 and 1954 Int J Cancer 58 4 1994 512 516
46. D. Wang, and R.N. Dubois The role of COX-2 in intestinal inflammation and colorectal cancer Oncogene 29 6 2010 781 788
47. A. Mantovani, and M.A. Pierotti Cancer and inflammation: a complex relationship Cancer Lett 267 2 2008 180 181
48. S.M. Weis, and D.A. Cheresh Tumor angiogenesis: molecular pathways and therapeutic targets Nat Med 17 11 2011 1359 1370
49. N. Ferrara Vascular endothelial growth factor Arterioscler Thromb Vasc Biol 29 6 2009 789 791
50. B. Millauer High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis Cell 72 1993 835 846
51. C. Gialeli, A.D. Theocharis, and N.K. Karamanos Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting FEBS J 278 1 2011 16 27
52. S. Silletti Disruption of matrix metalloproteinase 2 binding to integrin à v á 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo Proc Natl Acad Sci U.S.A 98 1 2001 119 124
53. N.M. Kofler Notch signaling in developmental and tumor angiogenesis Genes Cancer 2 12 2011 1106 1116
54. A. Abramsson, P. Lindblom, and C. Betsholtz Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors J Clin Invest 112 8 2003 1142 1151
55. A.N. Brooks, E. Kilgour, and P.D. Smith Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer Clin Cancer Res 18 7 2012 1855 1862
56. C. Fischer Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels Cell 131 3 2007 463 475
57. M. Snuderl Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma Cell 152 5 2013 1065 1076
58. D. Gerald Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy Cancer Res 73 6 2013 1649 1657
59. P. Salven Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors Am J Pathol 153 1998 103 108
60. R. Valtola VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer Am J Pathol 154 5 1999 1381 1390
61. M. Skobe Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma Am J Pathol 159 3 2001 893 903
62. S.A. Stacker VEGF-D promotes the metastatic spread of tumor cells via the lymphatics Nature Med 7 2 2001 186 191
63. W. Debinski VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme Mol Med 7 2001 598 608
64. L.M. Wise Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens J Biol Chem 278 39 2003 38004 38014
65. S.A. Stacker Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers J Biol Chem 274 45 1999 32127 32136
66. V. Joukov Proteolytic processing regulates receptor specificity and activity of VEGF-C EMBO J 16 1997 3898 3911
67. B.K. McColl Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D J Exp Med 198 6 2003 863 868
68. B.K. McColl Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2 FASEB J 21 4 2007 1088 1098
69. M.E. Baldwin Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis J Biol Chem 276 47 2001 44307 44314
70. V. Joukov A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases EMBO J 15 2 1996 290 298
71. M.G. Achen Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) Proc Natl Acad Sci U.S.A 95 2 1998 548 553
72. T. Veikkola Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice EMBO J 20 6 2001 1223 1231
73. M. Jeltsch Hyperplasia of lymphatic vessels in VEGF-C transgenic mice Science 276 1997 1423 1425
74. M. Wirzenius Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting J Exp Med 204 6 2007 1431 1440
75. S.J. Mandriota Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis EMBO J 20 4 2001 672 682
76. L. Kopfstein Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis Am J Pathol 170 4 2007 1348 1361
77. A. Gogineni Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis PLoS One 8 7 2013 e68755
78. S.A. Stacker, R.A. Williams, and M.G. Achen Lymphangiogenic growth factors as markers of tumor metastasis APMIS 112 2004 539 549
79. R.H. Farnsworth, M.G. Achen, and S.A. Stacker Lymphatic endothelium: an important interactive surface for malignant cells Pulm Pharmacol Ther 19 1 2006 51 60
80. S. Hirakawa VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites Blood 109 3 2007 1010 1017
81. M.G. Achen, G.B. Mann, and S.A. Stacker Targeting lymphangiogenesis to prevent tumour metastasis Br J Cancer 94 10 2006 1355 1360
82. S.A. Stacker, and M.G. Achen From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy Lymphat Res Biol 6 3-4 2008 165 172
83. M.G. Achen, and S.A. Stacker Molecular control of lymphatic metastasis Ann N Y Acad Sci 1131 2008 225 234
84. S. Schulte-Merker, A. Sabine, and T.V. Petrova Lymphatic vascular morphogenesis in development, physiology, and disease J Cell Biol 193 4 2011 607 618
85. T. Tammela, and K. Alitalo Lymphangiogenesis: molecular mechanisms and future promise Cell 140 4 2010 460 476
86. A.S. Lee Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis Cancer Res 71 13 2011 4506 4517
87. N.O. Karpinich Adrenomedullin gene dosage correlates with tumor and lymph node lymphangiogenesis FASEB J 27 2 2013 590 600
88. R.N. DuBois The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers Carcinogenesis 19 1 1998 49 53
89. D.G. Menter, and R.N. Dubois Prostaglandins in cancer cell adhesion, migration, and invasion Int J Cell Biol 2012 2012 723419
90. C. Yokoyama, T. Takai, and T. Tanabe Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence FEBS Lett 231 2 1988 347 351
91. D.A. Kujubu TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue J Biol Chem 266 20 1991 12866 12872
92. T. Hla, and K. Neilson Human cyclooxygenase-2 cDNA Proc Natl Acad Sci U S A 89 16 1992 7384 7388
93. G.P. Eberhart Insulin sensitivity of adipocytes from inbred mouse strains resistant or sensitive to diet-induced obesity Am J Physiol 266 5 Pt 2 1994 R1423 R1428
94. H. Sano Expression of cyclooxygenase-1 and -2 in human colorectal cancer Cancer Res 55 17 1995 3785 3789
95. T. Hida Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas Cancer Res 58 17 1998 3761 3764
96. D. Hwang Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer J Natl Cancer Inst 90 6 1998 455 460
97. O.N. Tucker Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer Cancer Res 59 5 1999 987 990
98. G. Chan Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck Cancer Res 59 5 1999 991 994
99. H.H. Tai Structure and function of human NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase Adv Exp Med Biol 507 2002 245 250
100. M.G. Backlund, J.R. Mann, and R.N. Dubois Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2 Oncology 69 Suppl. 1 2005 28 32
101. M. Yan 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers Proc Natl Acad Sci U S A 101 50 2004 17468 17473
102. I. Wolf 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer Cancer Res 66 15 2006 7818 7823
103. B. Rigas, I.S. Goldman, and L. Levine Altered eicosanoid levels in human colon cancer J Lab Clin Med 122 5 1993 518 523
104. S. Pugh, and G.A. Thomas Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2 Gut 35 5 1994 675 678
105. A. Greenhough The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis 30 3 2009 377 386
106. M. Sonoshita Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice Nat Med 7 9 2001 1048 1051
107. M. Mutoh Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis Cancer Res 62 1 2002 28 32
108. H. Amano Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth J Exp Med 197 2 2003 221 232
109. A.M. Fulton, X. Ma, and N. Kundu Targeting prostaglandin E EP receptors to inhibit metastasis Cancer Res 66 20 2006 9794 9797
110. K. Watanabe Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice Cancer Lett 156 1 2000 57 61
111. D. Holt Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4 Cancer Immunol Immunother 60 11 2011 1577 1586
112. D. Wang, and R.N. Dubois Prostaglandins and cancer Gut 55 1 2006 115 122
113. M. Ahmadi, D.C. Emery, and D.J. Morgan Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo Cancer Res 68 18 2008 7520 7529
114. E. Scandella Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells Blood 100 4 2002 1354 1361
115. M. Oshima Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 5 1996 803 809
116. M. Tsujii Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 1998 705 716
117. H. Seno Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps Cancer Res 62 2 2002 506 511
118. M. Kamiyama EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival Oncogene 25 53 2006 7019 7028
119. G. Davies Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention Ann Oncol 13 5 2002 669 678
120. R. Fujiwaki Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase Hum Pathol 33 2 2002 213 219
121. Y.E. Joo Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer J Clin Gastroenterol 37 1 2003 28 33
122. J. Zhang Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients Biomed Pharmacother 59 Suppl. 2 2005 S285 S288
123. A.V. Timoshenko COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer Br J Cancer 94 8 2006 1154 1163
124. L.T. Soumaoro Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis Dis Colon Rectum 49 3 2006 392 398
125. J.L. Su Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma Cancer Res 64 2 2004 554 564
126. C. Iwata Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis Cancer Res 67 21 2007 10181 10189
127. K. Hosono Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation Arterioscler Thromb Vasc Biol 31 5 2011 1049 1058
128. D. Chakroborty Catecholamines regulate tumor angiogenesis Cancer Res 69 9 2009 3727 3730
129. S.W. Cole Transcript origin analysis identifies antigen-presenting cells as primary targets of socially regulated gene expression in leukocytes Proc Natl Acad Sci U S A 108 7 2011 3080 3085
130. S.K. Lutgendorf Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma Clin Cancer Res 14 21 2008 6839 6846
131. M. Moreno-Smith Biologic effects of dopamine on tumor vasculature in ovarian carcinoma Neoplasia 15 5 2013 502 510
132. I.C. Roddie Lymphatic motility Lymphology 13 4 1980 166 172
133. N.G. McHale Lymphatic innervation Blood Vessels 27 2-5 1990 127 136
134. K.S. Madden, M.J. Szpunar, and E.B. Brown Beta-adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines Breast Cancer Res Treat 130 3 2011 747 758
135. C.N. Landen Jr. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer Cancer Res 67 21 2007 10389 10396
136. M. Shi Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer Mol Cancer 9 2010 269
137. E.V. Yang Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells Cancer Res 66 21 2006 10357 10364
138. A.K. Sood Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis J Clin Invest 120 5 2010 1515 1523
139. K.S. Sastry Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation J Biol Chem 282 19 2007 14094 14100
140. M.M. Halford, N.C. Tebbutt, and J. Desai Towards the biomarker-guided rational use of anti-angiogenic agents in the treatment of metastatic colorectal cancer Colorectal Cancer 1 2 2012 149 161
141. N. Ferrara Targeting VEGF-A to treat cancer and age-related macular degeneration Annu Rev Med 58 2007 491 504
142. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 5706 2005 58 62
143. K.K. Ciombor, J. Berlin, and E. Chan Aflibercept Clin Cancer Res 19 8 2013 1920 1925
144. A.S. Chung, X. Wu, and G. Zhuang An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy Nature Med 19 9 2013 1114 1123
145. N. Davydova The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding J Mol Biol 407 4 2011 581 593
146. K. Persaud Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C J Cell Science 117 Pt 13 2004 2745 2756
147. M. Caunt Blocking neuropilin-2 function inhibits tumor cell metastasis Cancer Cell 13 4 2008 331 342
148. Y. He Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling J Natl Cancer Inst 94 11 2002 819 825
149. T. Holopainen Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis J Natl Cancer Inst 104 6 2012 461 475
150. G. Procopio Experience with sorafenib in the treatment of advanced renal cell carcinoma Ther Adv Urol 4 6 2012 303 313
151. J. Verweij, and S. Sleijfer Pazopanib, a new therapy for metastatic soft tissue sarcoma Expert Opin Pharmacother 14 7 2013 929 935
152. P. Mankal, and E. O'Reilly Sunitinib malate for the treatment of pancreas malignancies - where does it fit? Expert Opin Pharmacother 14 6 2013 783 792
153. V. Grunwald, and A.S. Merseburger Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment Onco Targets Ther 5 2012 111 117
154. S.L. Davis The development of regorafenib and its current and potential future role in cancer therapy Drugs Today (Barc) 49 2 2013 105 115
155. C.M. Ulrich, J. Bigler, and J.D. Potter Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics Nat Rev Cancer 6 2 2006 130 140
156. R.N. DuBois Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas Gastroenterology 108 4 1995 1310 1314
157. M.J. Thun, S.J. Henley, and C. Patrono Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 94 4 2002 252 266
158. P.M. Rothwell, J.F. Price, and F.G. Fowkes Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 9826 2012 Apr 28 1602 1612
159. P.M. Rothwell Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Lancet 379 2012 1591 1601
160. G.A. Kune, S. Kune, and L.F. Watson Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study Cancer Res 48 15 1988 4399 4404
161. M.J. Thun, E.J. Jacobs, and C. Patrono The role of aspirin in cancer prevention Nat Rev Clin Oncol 9 5 2012 Apr 3 259 267
162. P.M. Rothwell Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 9759 2011 31 41
163. M.F. Leitzmann Aspirin use in relation to risk of prostate cancer Cancer Epidemiol Biomarkers Prev 11 10 Pt 1 2002 1108 1111
164. T.M. Brasky Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study Cancer Causes Control 21 9 2010 1503 1512
165. H.A. Hirsch A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases Cancer Cell 17 4 2010 348 361
166. M.D. Holmes Aspirin intake and survival after breast cancer J Clin Oncol 28 9 2010 1467 1472
167. B.H. von Rahden Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma Cancer Res 65 12 2005 5038 5044
168. G.L. Guo The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer Zhonghua Wai Ke Za Zhi 46 2 2008 132 135
169. H. Kubo Spontaneous regression of recurrent and metastatic Merkel cell carcinoma J Dermatol 34 11 2007 773 777
170. H. Liu Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C Anat Rec (Hoboken) 292 10 2009 1577 1583
171. J.W. Black A new adrenergic betareceptor antagonist Lancet 1 7342 1964 1080 1081
172. J.W. Lee Surgical stress promotes tumor growth in ovarian carcinoma Clin Cancer Res 15 8 2009 2695 2702
173. B. Benjamin Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats Int J Colorectal Dis 25 12 2010 1459 1464
174. A. Melhem-Bertrandt Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer J Clin Oncol 29 19 2011 2645 2652
175. E. Botteri Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women Breast Cancer Res Treat 140 3 2013 567 575
176. P.A. Ganz Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort Breast Cancer Res Treat 129 2 2011 549 556
177. G.V. Sorensen Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study J Clin Oncol 31 18 2013 2265 2272
178. D.G. Powe Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival Oncotarget 1 7 2010 628 638
179. Y.K. Chae Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes J Cancer 4 7 2013 549 556
180. Y.K. Chae Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins Cancer Invest 29 9 2011 585 593
181. H.H. Grytli Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease Eur Urol 2013 S0302-2838(13) 00010-9
182. H.H. Grytli Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy Prostate 73 3 2013 250 260
183. R.S. Kerbel Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer J Mammary Gland Biol Neoplasia 17 3-4 2012 229 239
184. T. Shan Beta2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction Eur J Pharmacol 665 1-3 2011 1 7
185. S.J. Priceman Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy Blood 115 7 2010 1461 1471